Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bohdan Czartorysky

Child & Adolescent Psychiatry Parsippany, NJ Medical Doctor

NPI 1457640609 CMS profile 111189

199 Pomeroy Rd, 2Nd Floor, Parsippany, NJ 07054

Open in the dashboard

General payments

$20,968

59 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bohdan Czartorysky of Parsippany, NJ is reported in the CMS Open Payments database as having received $20,968 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,199 30
2024 General $362 13
2023 General $104 6
2020 General $15 1
2019 General $289 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bohdan Czartorysky
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Bohdan Czartorysky were reported at $20,199. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Bohdan Czartorysky Child & Adolescent Psychiatry median Middle half National median
2019 $289 $129 $42–$419 $163
2020 $15 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $0 $124 $40–$382 $149
2023 $104 $130 $45–$420 $160
2024 $362 $141 $42–$490 $164
2025 $20,199 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $20,314 30 payments
  2. Janssen Pharmaceuticals, Inc $240 11 payments
  3. Otsuka America Pharmaceutical, Inc. $234 8 payments
  4. ITI, Inc. $89 4 payments
  5. Neurocrine Biosciences, Inc. $34 2 payments
  6. E.R. Squibb & Sons, L.L.C. $31 2 payments
  7. Lundbeck LLC $14 1 payment
  8. Alkermes, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,054 7 payments
  2. Food and Beverage $1,599 45 payments
  3. Travel and Lodging $236 6 payments
  4. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. UZEDY $20,099 24 payments
  2. INVEGA SUSTENNA $240 11 payments
  3. ABILIFY MAINTENA $235 8 payments
  4. AUSTEDO $119 4 payments
  5. CAPLYTA $89 4 payments
  6. ABILIFY ASIMTUFII $87 5 payments
  7. INGREZZA $34 2 payments
  8. INVEGA TRINZA $26 2 payments
  9. COBENFY $17 1 payment
  10. Austedo XR $17 1 payment
  11. Other $39 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,906

Median for Neuropsychiatry: 88

Drug cost

$1,190,142

Median for Neuropsychiatry: $2,689

Branded share of claims

18.9%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 106 $304,676
Invega Trinza Paliperidone Palmitate Brand 26 $252,981
Abilify Maintena Aripiprazole Brand 45 $145,049
Ingrezza Valbenazine Tosylate Brand 14 $106,798
Risperdal Consta Risperidone Microspheres Brand 25 $60,949
Aristada Aripiprazole Lauroxil Brand 15 $47,562
Risperidone Er Risperidone Microspheres Brand 18 $35,896
Austedo Deutetrabenazine Brand 11 $35,274
Aripiprazole Generic 149 $23,006
Olanzapine Generic 287 $20,614

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $153
$153 106 —
CAPLYTA
  • ITI, Inc. $48
$48 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $29
$29 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $17
$17 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $17
$17 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record